Severe Acute Respiratory Syndrome clinical trials
The registry lists 376 studies for Severe Acute Respiratory Syndrome across more than 10 countries. 15 are recruiting or about to start. 164 of them are mainly about Severe Acute Respiratory Syndrome (how this is decided). Per ClinicalTrials.gov, last updated 2026-10-30.
Get an email when these change. Save the Severe Acute Respiratory Syndrome studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
National Institute of Allergy and Infectious Diseases (NIAID) (20) · University of Minnesota (9) · Direction Centrale du Service de Santé des Armées (6) · CureVac (5) · Institut Pasteur (5) · University Hospital, Montpellier (5) · Lahore General Hospital (5) · Assistance Publique - Hôpitaux de Paris (4)
What is being tested here
Drugs under test in Severe Acute Respiratory Syndrome studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Tozorakimab | 1 | 1 | 1 |
| Medical Marijuana | 1 | 0 | 1 |
| Hydroxychloroquine | 0 | 12 | 14 |
| Ivermectin | 0 | 1 | 6 |
| Remdesivir | 0 | 3 | 5 |
| CVnCoV COVID-19 vaccine | 0 | 3 | 5 |
| Methylprednisolone | 0 | 2 | 5 |
| BNT162 Vaccine | 0 | 0 | 4 |
| Ritonavir | 0 | 1 | 4 |
| Losartan | 0 | 1 | 4 |
Drug classes tested here Angiotensin receptor blockers (ARBs) 5 · Corticosteroids 5 · Antimitotic agents 3
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
All 4, phase 3 first
- Nov 2027Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen · Phase 3 · AstraZeneca
- Mar 2027KIDney Injury in Times of COVID-19 (KIDCOV) · University of California, San Francisco
- Jul 2027Bio-Manguinhos/Fiocruz COVID-19 (mRNA) Vaccine Booster · The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)
- Oct 2027Imaging Immune Activation in COVID-19 · CellSight Technologies, Inc.
Who these studies take
Of the 7 Severe Acute Respiratory Syndrome studies recruiting now, 6 (86%) set no upper age limit and 0 (0%) stop at 75 or younger. 3 (43%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 2 (29%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 3 (43%) | 3 (43%) |
| 18 | 7 (100%) | 7 (100%) |
| 30 | 7 (100%) | 7 (100%) |
| 40 | 7 (100%) | 7 (100%) |
| 50 | 7 (100%) | 7 (100%) |
| 65 | 7 (100%) | 7 (100%) |
| 75 | 7 (100%) | 7 (100%) |
| 85 | 7 (100%) | 7 (100%) |
Across all 376 studies, recruiting or not: 15% stop at 75 or younger and 10% at 65; 15% take children; 1% are for women only and 1% for men only; 31% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
How long Severe Acute Respiratory Syndrome studies take
Of 42 phase 3 interventional studies under Severe Acute Respiratory Syndrome, half reached primary completion within 12 months of starting, counting those still running.
| Start to primary completion | Every sponsor | Industry | Non-industry |
|---|---|---|---|
| Phase 1 | 10 mo4–15 · 18 studies | — | — |
| Phase 1/2 | 5 mo3–13 · 11 studies | — | — |
| Phase 2 | 10 mo7–17 · 40 studies | — | 10 mo7–18 · 29 studies |
| Phase 3 | 12 mo5–17 · 42 studies | — | 11 mo5–16 · 32 studies |
| Interventional, no phase | 10 mo5–25 · 40 studies | — | 10 mo5–26 · 32 studies |
| Observational | 12 mo4–26 · 79 studies | — | 12 mo4–30 · 70 studies |
Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out
Studies
Recruiting first, then most recently updated. Showing 50 of 376. Browse all 376 → or search them.
- Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental OxygenRecruitingNCT05624450Phase 339 countries
- KIDney Injury in Times of COVID-19 (KIDCOV)Enrolling by invitationNCT047057661 country
- Clinical Multimodal Surveillance of Respiratory Syndrome PathogensRecruitingNCT076946481 country
- Bio-Manguinhos/Fiocruz COVID-19 (mRNA) Vaccine BoosterNot yet recruitingNCT07640308Phase 1
- Imaging Immune Activation in COVID-19RecruitingNCT04815096Phase 21 country
- Steroid Treatment for Severe Acute Respiratory Infection (STAR) TrialNot yet recruitingNCT07199192Phase 41 country
- Study of Viral Respiratory InfectionsNot yet recruitingNCT067643811 country
- Prevalence and Outcome of SARS-CoV-2 Infection & COVID-19 in Transplant Recipients: The COVITRA StudyRecruitingNCT045794711 country
- Immune Cells in Inflammatory Arthritis With Coronaviruses, Including COVID-19Enrolling by invitationNCT043630471 country
- Repurposed Approved and Under Development Therapies for Patients With Early-Onset COVID-19 and Mild SymptomsRecruitingNCT04727424Phase 31 country
- Bioaerosol Sampling Device (BSD) Clinical StudyRecruitingNCT060470671 country
- Extracellular Vesicles From Mesenchymal Cells in the Treatment of Acute Respiratory FailureNot yet recruitingNCT06002841Phase 1/21 country
- Expanded Access to Zofin for Patients With COVID-19AvailableNCT04657406
- Outcomes Mandate National Integration With Cannabis as MedicineRecruitingNCT03944447Phase 21 country
- Infection Tracking in Travellers. The Project Aims to Identify Profiles of Travel-associated Illness and to Follow up on Long-term Sequelae of Arboviral Infections and MalariaNot yet recruitingNCT046725771 country
- Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) Immune Kidney Transplant Study (COVID-19)CompletedNCT047475221 country
- SARS-COV-2 Seroprevalence and Seroconversion Among Employees of the Universitair Ziekenhuis Brussel Following mRNA COVID-19 VaccinationActive, not recruitingNCT04880174Not applicable1 country
- Mitoquinone/Mitoquinol Mesylate as Oral and Safe Postexposure Prophylaxis for Covid-19CompletedNCT05886816Phase 21 country
- SARS-Cov-2 (COVID-19) Nasal Pharyngeal and Oral Pharyngeal Wash (SNOW) TrialTerminatedNCT04802408Phase 2/31 country
- VERU-111 in the Treatment of SARS-Cov-2 Infection by Assessing Its Effect on the Proportion of Patients Who Die on StudyCompletedNCT04842747Phase 36 countries
- Use of Hydroxychloroquine Alone or Associated for Inpatients With SARS-CoV2 Virus (COVID-19)WithdrawnNCT04361461Phase 31 country
- Extracorporeal Membrane Oxygenation (ECMO) and Coronavirus Disease (COVID) 19CompletedNCT043975881 country
- Collection of the Thrombo-VaxCov CohortWithdrawnNCT048893261 country
- Safety, Tolerability, and Immunogenicity of Trivalent Coronavirus Vaccine Candidate VBI-2901aCompletedNCT05548439Phase 11 country
- Acute Respiratory Failure and COVID-19 in Real LifeCompletedNCT043074591 country
- COVID-19 Contact Study by Antigen Detection TestWithdrawnNCT04745533
- COVID-OUT: Early Outpatient Treatment for SARS-CoV-2 Infection (COVID-19)CompletedNCT04510194Phase 31 country
- COVID-19 Vaccine Response in Chronic Respiratory ConditionsCompletedNCT053130871 country
- Nitric Oxide Gas Inhalation in Severe Acute Respiratory Syndrome in COVID-19CompletedNCT04306393Phase 22 countries
- Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b2) in Chinese Healthy PopulationCompletedNCT04649021Phase 21 country
- Safety and Tolerability of COVID-19 Vaccine (ABNCoV2)CompletedNCT04839146Phase 11 country
- Direct Topical Lung T3 Treatment to Improve Outcome & Sequelae of COVID-19 Acute Respiratory Distress SyndromeWithdrawnNCT04725110Phase 21 country
- A US Study to Look at Loss of Work and Healthcare Costs for People Affected With Mild-to-moderate COVID 19 Who Have High Chances of the Disease Becoming SevereCompletedNCT070727931 country
- Efficacy of the Sit to Stand Test in the Decision to Hospitalize a Patient Consulting the Emergency Dept for COVID 19TerminatedNCT04730661Not applicable1 country
- Intermediate IND Severe Illness COVID-19 CPWithdrawnNCT04411602Phase 11 country
- ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19CompletedNCT04843761Phase 31 country
- Aviptadil for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial)CompletedNCT06729606Phase 31 country
- Remdesivir for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial)CompletedNCT06729593Phase 31 country
- Study of the Pathogenesis of Olfactory Disorders in COVID-19CompletedNCT043669341 country
- TAF/FTC for Pre-exposure Prophylaxis of COVID-19 in Healthcare Workers (CoviPrep Study)TerminatedNCT04405271Phase 31 country
- COVID-FIS: Pilot in COVID-19 (SARS-CoV-2) of Fisetin in Older Adults in Nursing HomesTerminatedNCT04537299Phase 21 country
- COVID19 SARS Vaccinations: Systemic Allergic Reactions to SARS-CoV-2 VaccinationsCompletedNCT04761822Phase 21 country
- Antibody Detection of Vaccine-Induced Secretory EffectsCompletedNCT048954751 country
- LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19)CompletedNCT04402957Phase 23 countries
- Dysphagia and Dysphonia Outcomes in SARS CoV-2 (COVID-19) Infection (DYADS Study)CompletedNCT045846581 country
- COVID-19 Persistence in StoolCompletedNCT045467761 country
- Prevention of COVID-19 Complications in High-risk Subjects Infected by SARS-CoV-2 and Eligible for Treatment Under a Cohort ATU ('Autorisation Temporaire d'Utilisation') OR or Authorisation for Early Access (AAP). A Prospectvie Cohort.CompletedNCT048854521 country
- Evaluation of the Efficacy, Safety and Immunogenicity of Inactivated COVID 19 Vaccine(TURKOVAC) in Healthy Population of 18 and 64 Years of Age (Both Inclusive):a Randomized, Double-blind, Phase IIb Clinical TrialWithdrawnNCT05035238Phase 21 country
- SARS-CoV-2 Human Challenge Characterisation StudyCompletedNCT04865237Not applicable1 country
- A Trial Evaluating the Safety and Effects of an RNA Vaccine ARCT-021 in Healthy AdultsTerminatedNCT04668339Phase 22 countries